Granules India rises on getting USFDA’s approval for Glycopyrrolate Oral Solution

21 Aug 2024 Evaluate

Granules India is currently trading at Rs. 687.60, up by 12.25 points or 1.81% from its previous closing of Rs. 675.35 on the BSE.

The scrip opened at Rs. 680.00 and has touched a high and low of Rs. 689.05 and Rs. 673.50 respectively. So far 18051 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 697.15 on 12-Aug-2024 and a 52 week low of Rs. 292.85 on 25-Aug-2023.

Last one week high and low of the scrip stood at Rs. 689.35 and Rs. 657.95 respectively. The current market cap of the company is Rs. 16574.38 crore.

The promoters holding in the company stood at 38.87%, while Institutions and Non-Institutions held 34.51% and 26.62% respectively.

Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Oral Solution 1mg/5mL filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company. 

It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution, 1 mg/5 mL of Merz Pharmaceuticals, LLC. Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients aged three to 16 years who have neurological conditions associated with problem drooling.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.